Mesoridazine
Mesoridazine
Mesoridazine (pronounced: meh-so-ri-da-zine) is a piperidine neuroleptic drug belonging to the class of phenothiazine derivatives, used in the treatment of schizophrenia. It is a metabolite of thioridazine. The drug is a medium-potency antipsychotic and was used in the treatment of psychotic disorders including schizophrenia, psychosis, and severe anxiety before it was withdrawn in many countries due to cardiac toxicity.
Etymology
The term "Mesoridazine" is derived from the Greek words "mesos" meaning "middle" and "ridazine" which is a common suffix for phenothiazine derivatives. The name signifies its position as a metabolite of thioridazine, a more commonly used phenothiazine derivative.
Pharmacology
Mesoridazine acts as an antagonist of certain adrenergic, dopaminergic, histaminergic, and serotonergic receptors, leading to its antipsychotic effects. It is known to have a medium potency as an antipsychotic compared to other drugs in the phenothiazine class.
Side Effects
Common side effects of Mesoridazine include drowsiness, dizziness, and dry mouth. More serious side effects may include cardiac arrhythmias, neuroleptic malignant syndrome, and tardive dyskinesia. Due to the risk of cardiac toxicity, Mesoridazine is typically reserved for patients who have not responded to other antipsychotic treatments.
Related Terms
External links
- Medical encyclopedia article on Mesoridazine
- Wikipedia's article - Mesoridazine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski